نتایج جستجو برای: pik3ca

تعداد نتایج: 2433  

2014
Gieri Cathomas

PIK3CA, the catalytic subunit of PI3K, is mutated in many different tumors, including colorectal cancer (CRC). Mutations of PIK3CA have been reported in 10-20% of CRC, about 80% of mutations found in two hot spots in exon 9 and exon 20. In RAS wild-type CRC, PIK3CA mutations have been associated with a worse clinical outcome and with a negative prediction of a response to targeted therapy by an...

2012
Xiaoyun Liao Teppei Morikawa Paul Lochhead Yu Imamura Aya Kuchiba Mai Yamauchi Katsuhiko Nosho Zhi Rong Qian Reiko Nishihara Jeffrey A. Meyerhardt Charles S. Fuchs Shuji Ogino

Purpose:Mutations in PIK3CA [the gene encoding the p110a catalytic subunit of phosphatidylinositide3-kinase (PI3K)] play an important role in colorectal carcinogenesis. Experimental evidence suggests that PIK3CA exon 9 and exon 20mutations trigger different biologic effects, and that concomitant mutations in both exons 9 and 20 synergistically enhance tumorigenic effects. Thus, we hypothesized ...

2011
Jessica R. Adams Keli Xu Jeff C. Liu Natalia M. Ruiz Agamez Amanda J. Loch Ruth G. Wong Wei Wang Katherine L. Wright Timothy F. Lane Eldad Zacksenhaus Sean E. Egan

PIK3CA, which codes for the p110a catalytic subunit of phosphatidylinositol 3-kinase, is one of the most frequently mutated genes in human breast cancer. Here, we describe a mouse model for PIK3CA-induced breast cancer by using the ROSA26 (R26) knock-in system, in which targeted Pik3ca alleles can be activated through transgenic expression of Cre recombinase. We mated Pik3ca and Pik3ca knock-in...

2017
Takashi Takeshita Yutaka Yamamoto Mutsuko Yamamoto-Ibusuki Mai Tomiguchi Aiko Sueta Keiichi Murakami Yoko Omoto Hirotaka Iwase

BACKGROUND The measurement of ESR1 and PIK3CA mutations in plasma cell-free DNA (cfDNA) has been studied as a non-invasive method to quickly assess and monitor endocrine therapy (ET) resistant metastatic breast cancer (MBC) patients. METHODS The subjects of this retrospective study were a total of 185 plasma samples from 86 estrogen receptor-positive BC patients, of which 151 plasma samples w...

Journal: :Cancer research 2005
Katsutoshi Oda David Stokoe Yuji Taketani Frank McCormick

The phosphatidylinositol 3'-kinase (PI3K) pathway is activated in many human cancers. In addition to inactivation of the PTEN tumor suppressor gene, mutations or amplifications of the catalytic subunit alpha of PI3K (PIK3CA) have been reported. However, the coexistence of mutations in these two genes seems exceedingly rare. As PTEN mutations occur at high frequency in endometrial carcinoma, we ...

Journal: :Cancer research 2008
Katherine Stemke-Hale Ana Maria Gonzalez-Angulo Ana Lluch Richard M Neve Wen-Lin Kuo Michael Davies Mark Carey Zhi Hu Yinghui Guan Aysegul Sahin W Fraser Symmans Lajos Pusztai Laura K Nolden Hugo Horlings Katrien Berns Mien-Chie Hung Marc J van de Vijver Vicente Valero Joe W Gray René Bernards Gordon B Mills Bryan T Hennessy

Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in cancer. By applying mass spectroscopy-based sequencing and reverse-phase protein arrays to 547 human breast cancers and 41 cell lines, we determined the subtype specificity and signaling effects of PIK3CA, AKT, and PTEN mutations and the effects of PIK3CA mutations on responsiveness to PI3K inhibition in vitro and on out...

Journal: :Molecular cancer research : MCR 2015
Jaclyn F Hechtman Justyna Sadowska Jason T Huse Laetitia Borsu Rona Yaeger Jinru Shia Efsevia Vakiani Marc Ladanyi Maria E Arcila

UNLABELLED The PI3K/AKT/mTOR pathway is activated through multiple mechanisms in colorectal carcinoma. Here, the clinicopathologic and molecular features of AKT1 E17K-mutated colorectal carcinoma in comparison with PIK3CA-mutated colorectal carcinoma are described in detail. Interestingly, in comparison with PIK3CA mutants, AKT1 E17K was significantly associated with mucinous morphology and con...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2017
Nina Ilic Kıvanç Birsoy Andrew J Aguirre Nora Kory Michael E Pacold Shambhavi Singh Susan E Moody Joseph D DeAngelo Nicole A Spardy Elizaveta Freinkman Barbara A Weir Aviad Tsherniak Glenn S Cowley David E Root John M Asara Francisca Vazquez Hans R Widlund David M Sabatini William C Hahn

Oncogenic PIK3CA mutations are found in a significant fraction of human cancers, but therapeutic inhibition of PI3K has only shown limited success in clinical trials. To understand how mutant PIK3CA contributes to cancer cell proliferation, we used genome scale loss-of-function screening in a large number of genomically annotated cancer cell lines. As expected, we found that PIK3CA mutant cance...

2011
Filip Janku J. Jack Lee Apostolia M. Tsimberidou David S. Hong Aung Naing Gerald S. Falchook Siqing Fu Rajyalakshmi Luthra Ignacio Garrido-Laguna Razelle Kurzrock

BACKGROUND Oncogenic mutations of PIK3CA, RAS (KRAS, NRAS), and BRAF have been identified in various malignancies, and activate the PI3K/AKT/mTOR and RAS/RAF/MEK pathways, respectively. Both pathways are critical drivers of tumorigenesis. METHODS Tumor tissues from 504 patients with diverse cancers referred to the Clinical Center for Targeted Therapy at MD Anderson Cancer Center starting in O...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2009
Kevin Kalinsky Lindsay M Jacks Adriana Heguy Sujata Patil Marija Drobnjak Umeshkumar K Bhanot Cyrus V Hedvat Tiffany A Traina David Solit William Gerald Mary Ellen Moynahan

PURPOSE In breast cancer, somatic mutations in the PIK3CA gene are common. The prognostic implication of these activating mutations remains uncertain as moderately sized studies have yielded variable outcomes. Our aim was to determine the prognostic implications of PIK3CA mutations in breast cancer. EXPERIMENTAL DESIGN Archival formalin-fixed paraffin-embedded primary breast tumors, from 590 ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید